Your browser doesn't support javascript.
Gestational diabetes mellitus in the COVID-19 pandemic: A retrospective study from Hangzhou, China.
Yin, Binbin; Wu, Kaiqi; Hu, Lingwei; Zheng, Wanlu; Zheng, Yidan; Duan, Xiuzhi; Zhu, Bo.
  • Yin B; Department of Laboratory Medicine, The Women's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Wu K; Department of Laboratory Medicine, The Women's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Hu L; Department of Genetics and Metabolism, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Zheng W; Department of Laboratory Medicine, The Women's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Zheng Y; Department of Laboratory Medicine, The Women's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Duan X; Department of Laboratory Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Zhu B; Department of Laboratory Medicine, The Women's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
J Diabetes ; 14(10): 711-720, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-2052157
ABSTRACT

AIMS:

Our study aimed to investigate changes in the prevalence of gestational diabetes mellitus (GDM) in the COVID-19 pandemic and postpandemic era and the risk of adverse pregnancy outcomes in pregnant women diagnosed with GDM during the blockade period.

METHODS:

First, we investigated changes in the prevalence of GDM and the population undergoing oral glucose tolerance tests (OGTT) after the COVID-19 pandemic. We then collected clinical information from pregnant women diagnosed with GDM to explore the risk of adverse pregnancy outcomes in pregnant women with GDM during the COVID-19 pandemic.

RESULTS:

After the COVID-19 pandemic, the proportion of pregnant women in the total number of outpatient OGTT tests decreased yearly. The ratio was 81.30%, 79.71%, and 75.48% from 2019 to 2021, respectively, with the highest proportion of pregnant women in February 2020 (92.03%). The prevalence of GDM was higher in March 2020 compared to the same period in 2019. However, from 2019 to 2021, the prevalence decreased year by year with 21.46%, 19.81%, and 18.48%, respectively. The risk of adverse pregnancy outcomes for pregnant women diagnosed with GDM during the most severe period of the COVID-19 pandemic did not differ from before the COVID-19 pandemic.

CONCLUSIONS:

After the COVID-19 pandemic, the prevalence of GDM increased during the most severe period of the epidemic, but the overall prevalence of GDM decreased year by year. In addition, the pandemic did not change the risk of adverse pregnancy outcomes in pregnant women with GDM.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes, Gestational / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Female / Humans / Pregnancy Country/Region as subject: Asia Language: English Journal: J Diabetes Journal subject: Endocrinology Year: 2022 Document Type: Article Affiliation country: 1753-0407.13324

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes, Gestational / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Female / Humans / Pregnancy Country/Region as subject: Asia Language: English Journal: J Diabetes Journal subject: Endocrinology Year: 2022 Document Type: Article Affiliation country: 1753-0407.13324